All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Duvelisib to be developed and commercialized for all oncology indications in China
By Sara Valente
Bookmark this article
On 25 September 2018 it was announced in a press release that duvelisib will be developed and commercialized by CSPC Pharmaceutical Group Limited in China for all oncology indications.
Duvelisib is the first oral dual inhibitor of phosphoinositide-3-kinase-delta (PI3K-δ) and PI3K-γ being developed by Verastem. The signed agreement with CSPC will mean that the Group will have exclusive development and commercialization rights of duvelisib holding the marketing authorization and product license.
This follows the recent US FDA approval of duvelisib for the treatment of adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two prior lines of therapy. It has also received accelerated approval by the US FDA for the treatment of adult patients with R/R follicular lymphoma.
- BusinessWire online. CSPC Pharmaceutical Group Limited and Verastem Oncology Sign Exclusive License Agreement for the Development and Commercialization of COPIKTRA™ (duvelisib) in China. https://www.businesswire.com/news/home/20180925006174/en [Accessed October 5 2018]
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox